Navigation Links
Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
Date:6/13/2010

ke Sipahi  et al  have their appropriate place in scientific research. However, these analyses have well-recognised limitations, such as combining study summaries rather than analyzing individual patient data.

Telmisartan is one of the most studied anti-hypertensives in clinical trials, which have all been made publicly available. It is widely used as medication to lower blood pressure and protect patients against severe cardiovascular events such as myocardial infarction and stroke.

About Telmisartan

In the US, telmisartan is marketed as MICARDIS® (telmisartan) tablets.  MICARDIS is a prescription medicine used to treat high blood pressure (hypertension), and in certain high-risk people aged 55 years and older, to help lower their risk of having certain cardiovascular problems such as stroke, heart attack, or death.  Talk to your doctor to see whether MICARDIS is appropriate for you.

IMPORTANT SAFETY INFORMATION

MICARDIS (telmisartan) tablets are not for pregnant women. Taking MICARDIS during pregnancy can cause injury and even death to your unborn baby.  If you get pregnant, stop taking MICARDIS and call your doctor right away.  If you plan to become pregnant or breastfeed, talk to your doctor about other ways to lower your blood pressure.  The most serious side effects of MICARDIS are low blood pressure and kidney problems. Other rare but serious side effects may occur. Before taking MICARDIS, tell your doctor if you have liver, kidney or heart problems, and about all other medications you are taking.  

Please see full prescribing information, including boxed WARNING, for MICARDIS.

You are encouraged to report negative side effects of prescription drugs to the FDA.  
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
2. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
3. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
6. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
7. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
8. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
9. Beckman Coulter Affirms 2009 Outlook
10. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
11. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... Dec. 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... completion of enrollment in its first Phase 2a ... observations confirmed the 1-month findings that were reported ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... MYL ) today announced that it has ... La Roche Inc. resolving litigation related to XELODA® Tablets, ... Capecitabine Tablets. This product is an orally administered chemotherapeutic ... colorectal cancers. Pursuant to the agreement, ...
... Texas, Sept. 21, 2011 SmallCapVoice.com, Inc. ... Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI), ... medical alarm system that allows the users ... pendant, is now available. The interview can ...
Cached Medicine Technology:Mylan Announces XELODA® Settlement and License Agreement 2A New Audio Interview with Medical Alarm Concepts Holdings, Inc., CEO, Howard Teicher, is now at SmallCapVoice.com 2
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... CARSON CITY, NV (PRWEB) December 15, 2014 ... new powerhouse company, JM Ocean Avenue. JM Ocean ... technology of the Veretekk online automated marketing system. ... by the June 2014 merger of Ocean Avenue and ... a more than $2 Billion per year company. , ...
(Date:12/15/2014)... December 15, 2014 South Florida’s leading urgent ... holidays can be a daze of hassle, hustle, and bustle ... while decking halls, to burns when making special meals and ... that can happen at any time. To prevent this season ... has made a list of helpful and healthful holiday tips ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... , ... Shield of Texas has designated Houston Northwest Medical Center as a Blue Distinction Center for ... ... Northwest Medical Center as a Blue Distinction Center for Knee and Hip Replacement. Blue Distinction ...
... ... ... , ... , , ...
... ... ... , , , , ... ...
... , ... ... , , , ... Avon ...
... The National Institutes of Health has awarded a two-year ... the Bradley Hasbro Children,s Research Center to better understand ... disease (IBD), a condition that causes chronic and painful ... grant, funded by the American Recovery and Reinvestment Act ...
... and health care providers need to step up their ... pressure and better treat those with the condition, which ... half of heart failures in the United States each ... Medicine. Policies that create environments which ...
Cached Medicine News:Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 4Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 2Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 3Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 4Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 2Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 3Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 4Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 5Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 2Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 3Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 4Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 5Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 6Health News:NIH grant will create behavioral health registry for pediatric inflammatory bowel disease 2Health News:NIH grant will create behavioral health registry for pediatric inflammatory bowel disease 3Health News:IOM report declares high blood pressure a neglected disease 2Health News:IOM report declares high blood pressure a neglected disease 3
... Intuition EMR Ophthalmology is a comprehensive ... tailored for ophthalmology practices. Intuition EMR ... but provides the tools to evaluate ... you to make better decisions and ...
... MaximEyes by First Insight is the ... records solution for eye care professionals. ... with Eyefinitys online servicesrequest VSP authorizations, ... MaximEyes offers EMR, scheduling, billing, demographics, ...
... latest in advanced cartridge mixing and delivery ... and mechanically injects all types of bone ... Revolution&trade line-up includes a large selection of ... in difficult to access areas. A new, ...
Simply stated, no bone cement can match the history of Simplex™. Simplex™ is the only cement with 40 years of proven clinical performance - trusted by tens of thousands of surgeons with o...
Medicine Products: